लंदन| यूरोपियन सोसाइटी फॉर मेडिकल ऑन्कोलॉजी के वार्षिक सम्मेलन में प्रस्तुत अध्ययनों के अनुसार, कोविड -19 के खिलाफ टीकाकरण कैंसर के रोगियों में प्रभावी है, जिनकी प्रतिरक्षा प्रणाली विभिन्न कैंसर विरोधी दवाओं से कमजोर हो जाती है। निष्कर्षों से पता चला कि कैंसर से पीड़ित व्यक्तियों में सामान्य आबादी की तुलना में किसी भी अधिक दुष्प्रभाव का अनुभव किए बिना टीकाकरण के लिए एक उपयुक्त, सुरक्षात्मक प्रतिरक्षा प्रतिक्रिया होती है। अप्रत्यक्ष साक्ष्य यह भी बताते हैं कि एक तीसरा बूस्टर शॉट इस रोगी आबादी के बीच सुरक्षा के स्तर को और बढ़ा सकता है।
वीओआईसीई नाम के एक अध्ययन से पता चला है कि कैंसर के मरीज जिन्होंने कोविड जैब लिया था, उन्हें मौजूदा ऑन्कोलॉजी उपचार की परवाह किए बिना सुरक्षित रखा गया था।
इस अध्ययन ने नीदरलैंड के कई अस्पतालों के 791 रोगियों को चार अलग-अलग अध्ययन समूहों में नामांकित किया, जिनमें कैंसर के बिना व्यक्ति, इम्यूनोथेरेपी के साथ इलाज किए गए कैंसर के रोगी, कीमोथेरेपी के साथ इलाज किए गए रोगियों और अंत में एक कीमो-इम्यूनोथेरेपी संयोजन के साथ इलाज किए गए रोगियों को मॉडर्न के दो के प्रति उनकी प्रतिक्रियाओं को मापने के लिए डोज एमआरएनए-1273 वैक्सीन में शामिल किया गया था।
इटली के मिलान में यूरोपियन इंस्टीट्यूट ऑफ ऑन्कोलॉजी में फेफड़े के कैंसर विशेषज्ञ डॉ एंटोनियो पासारो के अनुसार, ये परिणाम कैंसर के बिना व्यक्तियों के समूह के लगभग सभी (99.6 प्रतिशत) में देखी गई एंटीबॉडी प्रतिक्रियाओं के साथ अनुकूल रूप से तुलना करते हैं, जो अध्ययन में शामिल नहीं हैं।
उन्होंने कहा कि परीक्षण आबादी में देखे गए टीके की प्रभावकारिता की उच्च दर, कैंसर विरोधी उपचार के प्रकार की परवाह किए बिना, रोगियों और उनके डॉक्टरों के लिए एक मजबूत और आश्वस्त करने वाला संदेश है।
इसी तरह के परिणाम इजराइल में कैंसर के 232 रोगियों और 261 नियंत्रण विषयों के बीच टोजि़नामेरन (फाइजर-बायोएनटेक) के प्रभावों पर किए गए एक अन्य अध्ययन में पाए गए। कैंसर से पीड़ित एक तिहाई से भी कम (29 प्रतिशत) ने पहली खुराक प्राप्त करने के बाद एंटीबॉडी विकसित की, जबकि नियंत्रण समूह में 84 प्रतिशत की तुलना में, दूसरी खुराक के प्रशासन के बाद यह अनुपात बढ़कर 86 प्रतिशत हो गया।
उपरोक्त दोनों अध्ययनों ने वायरस के खिलाफ पर्याप्त सुरक्षात्मक एंटीबॉडी विकसित करने के लिए कैंसर के रोगियों के लिए कोविड वैक्स का दूसरा शॉट लेने की आवश्यकता पर भी जोर दिया।
न्यू इंग्लैंड जर्नल ऑफ मेडिसिन में प्रकाशित एक अध्ययन से पता चला है कि 60 वर्ष या उससे अधिक उम्र के लोगों पर एक बूस्टर शॉट, उनके टीकाकरण चक्र को पूरा करने के पांच महीने बाद, कोविड -19 और गंभीर बीमारी की घटनाओं को कम करता है।
डॉ लुइस कैस्टेलो ने कहा कि ये निष्कर्ष कैंसर के रोगियों को उनकी सुरक्षा में सुधार करने के लिए संभावित रूप से तीसरी बूस्टर खुराक सहित पूरे चक्र की पेशकश के सिद्धांत को अतिरिक्त समर्थन देते हैं, क्योंकि इससे पता चलता है कि उनकी प्रतिरक्षा प्रणाली अतिरिक्त उत्तेजना का जवाब देगी। ब्रैंको, मेडिकल ऑन्कोलॉजिस्ट, ईएसएमओ साइंटिफिक एंड मेडिकल डिवीजन, जो अध्ययन का हिस्सा नहीं थे।
यह भी पढ़े►कोविड के ठीक होने के बाद हर छह महीने में जांच करवाएं -शोध
World Alzheimer's Day- Constant exposure to noise pollution may increase the risk of dementia caused due to Alzheimer's disease while music could have positive impact, say doctors.
According to a recent study published in international health journals around the world, constant exposure to traffic noise increases the risk of dementia among aged population.
Each year, September 21 is commemorated as the World Alzheimer's Day, and Alzheimer's disease has been found to be the commonest cause of dementia.
Doctors say with India fast racing towards becoming the most populated country in the world, and with improved healthcare delivery mechanism, aged population is on the rise in the country. This section of the society is at the risk of developing age-related complications like dementia, which is often considered a serious mental problem caused by brain disease or injury, that affects the ability to think, remember and behave normally.
Commenting on the problem, Sritheja Reddy, Consultant Neurologist, Gleneagles Global Hospital believes that music usually has a soothing effect on individuals of all ages, but loud and persistent noise can cause mental disturbance, and could even trigger experiences of ill being among those people who are suffering from dementia or Alzheimer's related problems. "Cities are usually bustling with great activity during the day times and in the nights, but this could increase exposure to excessive noise, that can lead to short term impairments in cognitive function, particularly with respect to the ability to focus and remember. And the most important aspect here is that chronic exposure to noise pollution may increase the risk for dementia," the doctor said.
Abhinay M. Huchche, Consultant Neurologist, SLG Hospitals says that musical sounds could have a positive impact on people suffering from dementia, caused due to Alzheimer's disease." Listening to or singing songs can provide emotional and behavioral benefits for people with Alzheimer's disease and other types of dementia. Musical memories are often preserved in Alzheimer's disease because key brain areas linked to musical memory are relatively undamaged by the disease," he added.
Changala Praveen, Consultant - Neurophysician, Aware Gleneagles Global Hospital pointed out that ageing patients require extra attention, and those impacted by dementia require proper evaluation and management of the disease through a multidisciplinary approach. "Alzheimer's disease is the most common cause for dementia, and there are multiple reasons for aged population developing this problem. Constant exposure to loud and unsavoury sounds like traffic noise is also a major cause for the older people to develop dementia. People who have aged family members in the house must ensure the elderly are protected from loud noises, and this is the best solution to arrest complexities," he said.
Having exposure to high levels of noise during the night is especially concerning, as sleep is a critical period for mental and cognitive restoration. Fragmented sleep resulting from noise disturbance is associated with increased oxidative stress causes alterations in the immune system and increased systemic inflammation.
Read More► Are young Indians at a higher risk of heart disease?
London, Sep 6 (IANS) People who have modestly but measurably worse lung function are more likely to suffer sudden cardiac death (SCD), according to research presented at the European Respiratory Society International Congress.SCD is an unexpected death that results from a sudden malfunction in the heart and in many people who suffer SCD, there are no previous warning signs. Researchers hope their findings could help spot people at risk of SCD and prevent deaths in the future.The team at Lund University in Sweden studied a group of 28,584 middle-aged people with no known heart problems who were living in Malmo, Sweden and followed them for 40 years.They found that measurably lower lung function in middle-aged people was more strongly related to suffering a SCD (a 23 per cent increase in risk) than a non-fatal coronary event (an 8 per cent increase in risk) later on in life."Although sudden cardiac deaths are common, we don't know enough about who is at risk in the general population. There are links between lung and heart health, so we wanted to investigate whether measurable differences in lung function could offer clues about the risk of sudden cardiac death," said Dr Suneela Zaigham, researcher at the Department of Clinical Sciences at Lund University, Sweden."Our findings suggest that testing people's lungs when they are middle-aged and healthy could help spot those who have a higher risk of sudden cardiac death. This could enable people to take steps to potentially reduce the risk of this devastating event," Zaigham added.Smoking is also known to affect both lung and heart health, however the pattern of risk remained even in people who had never smoked, Zaigham said."This study suggests a link between lung health and sudden cardiac death. It shows a higher risk of fatal than non-fatal coronary events even in people whose lung function is moderately lower but may still be within a normal range," said Marc Humbert, who was not involved in the research, from the Universite Paris-Saclay, France."This is something we can measure fairly easily, meaning that lung function could be used as part of a screening tool," he suggested.--IANSrvt/dpb
New Delhi, Aug 20 (IANS) The All India Institute of Medical Sciences (AIIMS) administration is mulling over starting an AIIMS trauma centre for non-Covid patients in a phased manner as the daily fresh Covid caseload has substantially decreased in the national capital. Declaring the centre dedicated for Covid-19 treatment in March 2020, the trauma facilities were shifted to the main AIIMS building.The Resident Doctors Association (RDA) had written several times to the AIIMS administration to start the trauma service as the Covid caseload has decreased now. In a recently held meeting with the RDA, it has been proposed to start the trauma centre for non-Covid patients in a phased manner.However, the AIIMS RDA has raised objections over the phased manner plan for the trauma centre. An RDA official told IANS that they are receiving as many traumatic patients as during pre-Covid times. They have provided us just two to three wards to start the service which is not enough to handle all patients, said the RDA officials. "In a recent general body meeting held by AIIMS administration, it was decided to allocate some general wards at Jai Prakash Narayan Apex Trauma Centre (JPNATC) to cater to trauma patients. Emergency, Operative and ICU are three pillars of trauma care. Unavailability of these will result in an increase in preventable deaths. AIIMS administration in a recent decision has, however, denied the availability of emergency, ICU and operative care services to trauma victims at JPNATC" the RDA official said.The RDA says that the issues regarding trauma care prevalent at Main AIIMS such as delays in emergency operative intervention, transfer out of moderate to severe injury patients, etc, will remain the same.The official said during pre-Covid times there were total 264 beds, including 38 ICU beds at the Jai Prakash Narayan Trauma Centre; post-Covid it has been decreased to 95 beds, including 18 ICU beds. "Several buildings at AIMMS are fully unoccupied during the pandemic times where Covid services can be started", said the RDA officials.The RDA official said the RDA has requested AIIMS administration to restore trauma facilities at JPNATC in total.---IANSavr/khz/bg
Singapore, Aug 20 (IANS) Singapore will pilot a home isolation for fully vaccinated Covid-19 patients with mild or no symptoms soon, the Ministry of Health said in statement.With much more local and global data showing that fully vaccinated Covid-19 patients have a much lower risk of developing severe disease, "we are piloting a home-centric care model" from August 30, Xinhua news agency quoted the statement issued on Thursday as saying.These patients will spend the first few days in a medical facility before moving to home isolation. By then, the viral loads of vaccinated patients would have dropped, said the Ministry.The patients and their household members must both be fully vaccinated and must not belong to any vulnerable groups, such as the elderly or immunocompromised.These patients also need to have a suitable home setting, where they can be isolated from the rest of their household, the Ministry added.During Home Isolation, the patients and their household members are required to remain in their place of residence, and the patients will be provided with access to 24/7 telemedicine services.The patients will be subject to a Polymerase Chain Reaction (PCR) swab on the ninth day of illness to determine if they could be discharged from isolation, while all household members will be placed on a daily Antigen Rapid Test (ART) testing regimen for early detection of potential infection.The Ministry said they would closely monitor the pilot's outcomes, and study if more patients may benefit from this mode of recovery in a safe manner.It also announced Thursday a series of measures to further ease the community measures to contain the spread of the virus. The easing involves mainly increasing the size of masked-on events and religious services.According to the Ministry, 77 per cent of the population has received two doses of Covid-19 vaccines, and 82 per cent has received at least one dose.--IANSksk/
Washington, Aug 19 (IANS) Early administration of convalescent plasma does not prevent disease progression in a high-risk group of Covid-19 patients, says a study led by US National Institutes of Health (NIH).The trial, launched in August 2020, was stopped in February 2021 due to lack of efficacy based on a planned interim analysis. The final study has been published online in The New England Journal of Medicine."We were hoping that the use of Covid-19 convalescent plasma would achieve at least a 10 per cent reduction in disease progression in this group, but instead, the reduction we observed was less than 2 per cent," said Clifton Callaway, principal investigator for the trial."That was surprising to us. As physicians, we wanted this to make a big difference in reducing severe illness and it did not," said Callaway, who is also professor of emergency medicine at the University of Pittsburgh in the US.Covid-19 convalescent plasma, also known as "survivor's plasma", is blood plasma derived from patients who have recovered from Covid-19. Last year, the US Food and Drug Administration (FDA) issued an emergency use authorisation to allow use of convalescent plasma in hospitalised patients with Covid-19.The randomised, controlled clinical trial involved 500 adult outpatients who presented to 48 emergency departments with mild Covid-19 symptoms during their first week post-infection in the US.The researchers randomly assigned the participants to receive treatment with either high-titre Covid-19 convalescent plasma (containing anti-Covid-19 antibodies) or placebo (salt solution infused with multivitamins and lacking antibodies).Of the 511 participants, disease progression occurred in 77 (30 per cent) in the Covid-19 plasma group compared with 81 patients (31.9 per cent) in the placebo group. The plasma intervention did not cause harm, the researchers found.The reason the intervention did not produce the expected results is unclear, Callaway said. Researchers are continuing to look at possible explanations, including insufficient plasma dose, timing of plasma administration, host-related factors, or other aspects of the host tissue responses to the infection, he added.Additional studies of Covid-19 convalescent plasma are ongoing or planned in different populations. The results will help get a clearer, more conclusive picture of its value for future treatments of Covid-19, the researchers said.--IANSrvt/vd